Acceleron Pharma (XLRN) Tops Q2 EPS by 17c

Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.32), $0.17 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $5.72 million versus the consensus estimate of $4.23 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery